All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-02-21T14:31:27.000Z

FDA grants ivosidenib priority review for the treatment of patients with newly diagnosed IDH1-mutant acute myeloid leukemia

Feb 21, 2019
Share:

Bookmark this article

On 20 February 2019, the US Food and Drug Administration (FDA) accepted a supplemental new drug application (sNDA) and granted priority review to ivosidenib, a first-in-class, oral, selective inhibitor of mutations in isocitrate dehydrogenase-1 (IDH1), for the treatment of patients with newly diagnosed IDH1-mutant acute myeloid leukemia (AML). This comes after ivosidenib received FDA approval for the treatment of patients with IDH1-mutant relapsed/refractory AML.

The sNDA for ivosidenib was based on the first-in-human phase I dose-escalation and expansion study (NCT02074839), which assessed the safety and efficacy of single-agent ivosidenib in patients with previously untreated AML. The results from this trial showed that single-agent ivosidenib therapy induced an overall response rate of 57.6% (95% CI, 39.2–74.5) among newly diagnosed patients with IDH1-mutant AML. Furthermore, ivosidenib was shown to induce IDH1 mutational clearance in bone marrow mononuclear cells in 64% of patients who achieved complete remission (CR) or CR with partial hematologic recovery (CRh). Data from this trial was presented at the 60th Annual Society of Hematology Annual Meeting and Exposition, read more here.

According to the drug manufacturers, ivosidenib treatment regimens could “benefit from this targeted therapy”, as at present patients with newly diagnosed IDH1-mutant AML “are currently offered only palliative care.”

  1. TargetedOnc. Ivosidenib receives priority review from FDA for frontline IDH1+ AML. https://www.targetedonc.com/news/ivosidenib-receives-priority-review-from-fda-for-frontline-idh1-aml [Accessed 2019 Feb 21]

Newsletter

Subscribe to get the best content related to AML delivered to your inbox